Document is current
Any future updates will be listed below
-
Authors
Batty, Paul https://orcid.org/0000-0002-9807-5099
Beneder, Hannah
Schätz, Caroline https://orcid.org/0000-0002-8391-8778
Onea, Gabriel
Zaczek, Maciej https://orcid.org/0000-0001-9728-6401
Kutschat, Ana P. https://orcid.org/0000-0002-6360-873X
Abele, Miriam
Müller, Sophie https://orcid.org/0000-0003-3527-6739
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
Seruggia, Davide https://orcid.org/0000-0001-5014-0499
- License Information
-
More Information
Article History
Received: 22 July 2025
Accepted: 26 March 2026
First Online: 20 April 2026
Competing interests
: G.S.-F. and G.E.W. are scientific founders and shareholders of Proxygen and Solgate Therapeutics and shareholders of Cellgate Therapeutics. G.E.W. is on the Scientific Advisory Board of Proxygen and Nexo Therapeutics. The Winter and Superti-Furga laboratories have received research funding from Pfizer. G.E.W. is an inventor on several patents and patent applications covering small molecule degraders and degrader discovery approaches. The remaining authors declare no competing interests.
